2018 Disease Protein Expression Trials 
The Pharma Data
SEPTEMBER 28, 2021
Also, the info from SRP-9001 have helped to optimise the planning of the upcoming phase III clinical trial trial for DMD,” said Levi Garraway, M.D., Our goal is to still lead the way in developing transformative medicines for neuromuscular diseases. Roche’s Chief medic and Head of worldwide development.
The Pharma Data
JANUARY 13, 2021
we determined the crystal structure of CD40-ligand 2 , developed a humanized version of our antibody (hu5c8, ruplizumab, or Antova®) and tested it in human trials for preventing organ transplant rejection and autoimmunity. CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 30, 2024
Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43
Drug Discovery World
JANUARY 23, 2023
Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. DS: How will your work ultimately impact disease treatment?
Drug Discovery World
SEPTEMBER 5, 2022
Modulations in protein expression levels or the presence of dysfunctional proteins observed in individuals with specific mutations act as biomarkers in selecting patients for targeted therapies. . When selecting patients for therapy, we currently look at variants that directly affect protein expression or function.
The Pharma Data
APRIL 8, 2021
OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs). Following U.S.
The Pharma Data
SEPTEMBER 2, 2020
Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. Roche’s Chief Medical Officer and Head of Global Product Development.
Expert insights. Personalized for you.
52 
Let's personalize your content